U.S. markets closed
  • S&P 500

    3,855.36
    +13.89 (+0.36%)
     
  • Dow 30

    30,960.00
    -36.98 (-0.12%)
     
  • Nasdaq

    13,635.99
    +92.93 (+0.69%)
     
  • Russell 2000

    2,163.27
    -5.49 (-0.25%)
     
  • Crude Oil

    52.77
    +0.50 (+0.96%)
     
  • Gold

    1,854.60
    -1.60 (-0.09%)
     
  • Silver

    25.38
    -0.18 (-0.69%)
     
  • EUR/USD

    1.2142
    -0.0033 (-0.27%)
     
  • 10-Yr Bond

    1.0400
    -0.0510 (-4.67%)
     
  • GBP/USD

    1.3664
    -0.0020 (-0.15%)
     
  • USD/JPY

    103.7640
    +0.0030 (+0.00%)
     
  • BTC-USD

    32,920.06
    -527.18 (-1.58%)
     
  • CMC Crypto 200

    661.98
    -14.92 (-2.20%)
     
  • FTSE 100

    6,638.85
    -56.22 (-0.84%)
     
  • Nikkei 225

    28,822.29
    +190.84 (+0.67%)
     

Eurofins Genomics Launches Cost-Effective SARS-CoV-2 full-length Viral Genome Sequencing Services Essential in the Identification of Viral Mutations

·2 min read

Eurofins Genomics (Paris:ERF) launches an optimised, cost-effective, SARS-CoV-2, next-generation sequencing service providing full length viral genome sequences. The best-in-class ARTIC NGS Oligo mix synthesized by Eurofins Genomics’ Synthesis branch will be commercially available shortly. The new NGS service and ARTIC NGS oligo kit are Eurofins’ latest additions to a comprehensive product portfolio to support researchers globally in the development of vaccines and in their fight against the COVID-19 pandemic.

The increasing diversity of SARS-CoV-2 variants and the potential threat of increased virulence, higher infectivity and altered epitopes of these newly evolving viral strains, underline the need to identify, trace and track mutations over the complete viral genome. Whole genome SARS-CoV-2 sequencing identify mutant strains and spot emerging risks, including potentially immune and vaccine evasive variants, at an early stage.

The service and oligo mix are based on a protocol by the ARTIC consortium, which is used for SARS-CoV-2 sequencing worldwide. The ARTIC approach utilises an oligo pool for multiplexed PCR amplification of the complete viral genome. Eurofins Genomics optimised the formulation of the oligo pool achieving highest performance and best-in-class uniformity of coverage for the full-length viral genome.

Eurofins Genomics’ sophisticated bioinformatic pipeline assembles and compares the resulting contiguous full-length SARS-CoV-2 isolate sequences and delivers a report for conclusive interpretation. The new service exploits Eurofins Genomics scalable, automated, standardized laboratory information management system (LIMS) controlled high throughput next generation sequencing facility.

As announced on 23 December 2020, Eurofins is offering part of its sequencing capacity for free to public healthcare authorities who do not have emergency budgets available to detect the VUI2020-12/01 strain reported to be currently fast-spreading in the UK.

To learn more, please visit here.

For more information, please visit www.eurofins.com

Notes for the editor:

About Eurofins – the global leader in bio-analysis

Eurofins is the global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services and one of the global leaders in testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and in molecular clinical diagnostic testing.

With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods. Eurofins Shares are listed on Euronext Paris Stock Exchange.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201228005193/en/

Contacts

Investor Relations
Eurofins Scientific SE
E-mail: ir@eurofins.com